An ongoing phase I/II trial study (NCT02912949) is evaluating the activity and safety of Zenocutuzumab (MCLA-128), an anti-HER2/3 antibody, in patients with solid tumors, including NSCLC, harboring NRG1 fusion. This evidence concerns the gene NRG1 and non-small cell lung carcinoma.